Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas.

Shin H, Sa JK, Bae JS, Koo H, Jin S, Cho HJ, Choi SW, Kyoung JM, Kim JY, Seo YJ, Joung JG, Kim NKD, Son DS, Chung J, Lee T, Kong DS, Choi JW, Seol HJ, Lee JI, Suh YL, Park WY, Nam DH.

Cancer Res Treat. 2019 May 7. doi: 10.4143/crt.2019.036. [Epub ahead of print]

2.

The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival.

Zhang J, Caruso FP, Sa JK, Justesen S, Nam DH, Sims P, Ceccarelli M, Lasorella A, Iavarone A.

Commun Biol. 2019 Apr 23;2:135. doi: 10.1038/s42003-019-0369-7. eCollection 2019.

3.

PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma.

Shin YJ, Sa JK, Lee Y, Kim D, Chang N, Cho HJ, Son M, Oh MYT, Shin K, Lee JK, Park J, Jo YK, Kim M, Paddison PJ, Tergaonkar V, Lee J, Nam DH.

J Exp Med. 2019 May 6;216(5):1120-1134. doi: 10.1084/jem.20172170. Epub 2019 Mar 21.

4.

Ly6G+ inflammatory cells enable the conversion of cancer cells to cancer stem cells in an irradiated glioblastoma model.

Jeon HY, Ham SW, Kim JK, Jin X, Lee SY, Shin YJ, Choi CY, Sa JK, Kim SH, Chun T, Jin X, Nam DH, Kim H.

Cell Death Differ. 2019 Feb 25. doi: 10.1038/s41418-019-0282-0. [Epub ahead of print]

PMID:
30804471
5.

Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations.

Sa JK, Choi SW, Zhao J, Lee Y, Zhang J, Kong DS, Choi JW, Seol HJ, Lee JI, Iavarone A, Rabadan R, Nam DH.

Int J Cancer. 2019 Jun 15;144(12):3023-3030. doi: 10.1002/ijc.32054. Epub 2019 Jan 7.

6.

Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.

Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, Wang K, Wang Z, Nam Y, Jiang B, Sa JK, Cho HJ, Her NG, Zhang C, Zhao Z, Zhang Y, Zeng F, Wu F, Kang X, Liu Y, Qian Z, Wang Z, Huang R, Wang Q, Zhang W, Qiu X, Li W, Nam DH, Fan X, Wang J, Jiang T.

Cell. 2018 Nov 29;175(6):1665-1678.e18. doi: 10.1016/j.cell.2018.09.038. Epub 2018 Oct 18.

PMID:
30343896
7.

Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.

Lee JK, Liu Z, Sa JK, Shin S, Wang J, Bordyuh M, Cho HJ, Elliott O, Chu T, Choi SW, Rosenbloom DIS, Lee IH, Shin YJ, Kang HJ, Kim D, Kim SY, Sim MH, Kim J, Lee T, Seo YJ, Shin H, Lee M, Kim SH, Kwon YJ, Oh JW, Song M, Kim M, Kong DS, Choi JW, Seol HJ, Lee JI, Kim ST, Park JO, Kim KM, Song SY, Lee JW, Kim HC, Lee JE, Choi MG, Seo SW, Shim YM, Zo JI, Jeong BC, Yoon Y, Ryu GH, Kim NKD, Bae JS, Park WY, Lee J, Verhaak RGW, Iavarone A, Lee J, Rabadan R, Nam DH.

Nat Genet. 2018 Oct;50(10):1399-1411. doi: 10.1038/s41588-018-0209-6. Epub 2018 Sep 27.

PMID:
30262818
8.

A tension-mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma.

Barnes JM, Kaushik S, Bainer RO, Sa JK, Woods EC, Kai F, Przybyla L, Lee M, Lee HW, Tung JC, Maller O, Barrett AS, Lu KV, Lakins JN, Hansen KC, Obernier K, Alvarez-Buylla A, Bergers G, Phillips JJ, Nam DH, Bertozzi CR, Weaver VM.

Nat Cell Biol. 2018 Oct;20(10):1203-1214. doi: 10.1038/s41556-018-0183-3. Epub 2018 Sep 10.

PMID:
30202050
9.

Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma.

Cho HJ, Zhao J, Jung SW, Ladewig E, Kong DS, Suh YL, Lee Y, Kim D, Ahn SH, Bordyuh M, Kang HJ, Sa JK, Seo YJ, Kim ST, Lim DH, Dho YS, Lee JI, Seol HJ, Choi JW, Park WY, Park CK, Rabadan R, Nam DH.

Neuro Oncol. 2019 Jan 1;21(1):47-58. doi: 10.1093/neuonc/noy123.

PMID:
30085274
10.

Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma.

Sa JK, Kim SH, Lee JK, Cho HJ, Shin YJ, Shin H, Koo H, Kim D, Lee M, Kang W, Hong SH, Kim JY, Park YW, Song SW, Lee SJ, Joo KM, Nam DH.

Neuro Oncol. 2019 Feb 14;21(2):222-233. doi: 10.1093/neuonc/noy105.

PMID:
29939324
11.

Pharmacokinetics, Biodistribution, and Toxicity Evaluation of Anti-SEMA3A (F11) in In Vivo Models.

Lee J, Kim D, Son E, Yoo SJ, Sa JK, Shin YJ, Yoon Y, Nam DH.

Anticancer Res. 2018 May;38(5):2803-2810.

PMID:
29715102
12.

Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization.

Sim J, Nam DH, Kim Y, Lee IH, Choi JW, Sa JK, Suh YL.

Med Oncol. 2018 Mar 29;35(5):60. doi: 10.1007/s12032-018-1119-2.

PMID:
29600313
13.

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma.

Choi SW, Shin H, Sa JK, Cho HJ, Koo H, Kong DS, Seol HJ, Nam DH.

Cancer Med. 2018 May;7(5):1774-1783. doi: 10.1002/cam4.1439. Epub 2018 Mar 23.

14.

Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth.

Lee J, Shin YJ, Lee K, Cho HJ, Sa JK, Lee SY, Kim SH, Lee J, Yoon Y, Nam DH.

Cancer Res Treat. 2018 Jul;50(3):1009-1022. doi: 10.4143/crt.2017.315. Epub 2017 Nov 10.

15.

Antitumor activity, pharmacokinetics, tumor-homing effect, and hepatotoxicity of a species cross-reactive c-Met antibody.

Park H, Kim D, Son E, Shin S, Sa JK, Kim SH, Yoon Y, Nam DH.

Biochem Biophys Res Commun. 2017 Dec 9;494(1-2):409-415. doi: 10.1016/j.bbrc.2017.09.061. Epub 2017 Sep 14.

PMID:
28917835
16.

Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.

Park H, Kim D, Kim E, Sa JK, Lee HW, Yu S, Oh J, Kim SH, Yoon Y, Nam DH.

Int J Mol Sci. 2017 Sep 13;18(9). pii: E1968. doi: 10.3390/ijms18091968.

17.

Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBPβ Signaling.

Yin J, Oh YT, Kim JY, Kim SS, Choi E, Kim TH, Hong JH, Chang N, Cho HJ, Sa JK, Kim JC, Kwon HJ, Park S, Lin W, Nakano I, Gwak HS, Yoo H, Lee SH, Lee J, Kim JH, Kim SY, Nam DH, Park MJ, Park JB.

Cancer Res. 2017 Sep 15;77(18):4973-4984. doi: 10.1158/0008-5472.CAN-17-0388. Epub 2017 Jul 28.

18.

Spatiotemporal genomic architecture informs precision oncology in glioblastoma.

Lee JK, Wang J, Sa JK, Ladewig E, Lee HO, Lee IH, Kang HJ, Rosenbloom DS, Camara PG, Liu Z, van Nieuwenhuizen P, Jung SW, Choi SW, Kim J, Chen A, Kim KT, Shin S, Seo YJ, Oh JM, Shin YJ, Park CK, Kong DS, Seol HJ, Blumberg A, Lee JI, Iavarone A, Park WY, Rabadan R, Nam DH.

Nat Genet. 2017 Apr;49(4):594-599. doi: 10.1038/ng.3806. Epub 2017 Mar 6.

19.

Genomic and transcriptomic characterization of skull base chordoma.

Sa JK, Lee IH, Hong SD, Kong DS, Nam DH.

Oncotarget. 2017 Jan 3;8(1):1321-1328. doi: 10.18632/oncotarget.13616.

20.

Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy.

Kim DG, Kim KH, Seo YJ, Yang H, Marcusson EG, Son E, Lee K, Sa JK, Lee HW, Nam DH.

Oncotarget. 2016 May 17;7(20):29400-11. doi: 10.18632/oncotarget.8837.

21.

Involvement of DDX6 gene in radio- and chemoresistance in glioblastoma.

Cho YJ, Kang W, Kim SH, Sa JK, Kim N, Paddison PJ, Kim M, Joo KM, Hwang YI, Nam DH.

Int J Oncol. 2016 Mar;48(3):1053-62. doi: 10.3892/ijo.2016.3328. Epub 2016 Jan 11.

PMID:
26783102
22.

In vivo RNAi screen identifies NLK as a negative regulator of mesenchymal activity in glioblastoma.

Sa JK, Yoon Y, Kim M, Kim Y, Cho HJ, Lee JK, Kim GS, Han S, Kim WJ, Shin YJ, Joo KM, Paddison PJ, Ishitani T, Lee J, Nam DH.

Oncotarget. 2015 Aug 21;6(24):20145-59.

Supplemental Content

Support Center